Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir

• Κύριοι συγγραφείς: Supphachoke Khemla (Συγγραφέας), Atibordee Meesing (Συγγραφέας), Wantin Sribenjalux (Συγγραφέας), Ploenchan Chetchotisakd (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: AboutScience Srl, 2023-04-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Introduction: Human immunodeficiency virus (HIV) infection and the long-term use of antiretroviral therapy, especially efavirenz (EFV)-based regimens, impact lipid profiles due to insulin resistance and lead to a higher risk of metabolic diseases. Dolutegravir (DTG) is an integrase inhibitor with be...